Slingshot members are tracking this event:

Following Phase I/II trial results, Immunomedics (IMMU) to file sacituzumab govitecan for accelerated approval in triple-negative breast cancer in mid-2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
IMMU Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Sacituzumab Govitecan, Accelarated Approval, Triple-negative Breast Cancer, Phase 1/2